ArticleVaccines2024
Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis.Italian journal of pediatrics · 2025Pooled it
- Pooled it
- Review
- The Impact of Limited-Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (RSV) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study.Journal of paediatrics and child health · 2026Observational
- Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.The Journal of infectious diseases · 2026Article
- Real-world impact of nirsevimab on the epidemiology and severity of pediatric respiratory syncytial virus infections: a three-season cohort study in Italy.European journal of pediatrics · 2026Article
- Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective.Frontiers in pediatrics · 2026Article
- Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants.Human vaccines & immunotherapeutics · 2025Article
- Risk factors associated with severe RSV disease among hospitalized children in the second year of life: a multicenter study.European journal of pediatrics · 2025Article
- Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children.Communications medicine · 2025Article
- Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Review
- Burden and Economic Impact of Respiratory Viral Infections in Adults Aged 60 and Older: A Focus on RSV.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.